TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36154509

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intratympanic lidocaine (ITL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD2) (5 mg/ml)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD1) (2 mg/ml)
Number of subjects: 124
Study: 34010788

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 1067
Study: 32271467

Group type: EXPERIMENTAL
Intervention: 1-mL PRGF injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1-mL lidocaine injections
Number of subjects: 50
Study: 36267577

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) program, 12 weeks, 3-4 sessions per week, 3 sets of 10 repetitions at 60%-80% of 1-repetition maximum
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care including regular physiotherapy and use of orthotics
Number of subjects: 49
Study: 35752755

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance (Gp-Usg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional technique (Gp-Conv)
Number of subjects: 96
Study: 32464435

Group type: COMPARATOR
Intervention: Transcutaneous posterior tibial nerve stimulation (PTN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical stimulation (PS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (PTN and PS)
Number of subjects: 50
Study: 36263928

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla-300)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Insulin degludec 100 U/ml (IDeg-100)
Number of subjects: 343
Study: 32892235

Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 98
Study: 32609756

Group type: EXPERIMENTAL
Intervention: Adherence clubs (AC) intervention
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1060
Study: 35943370

Group type: EXPERIMENTAL
Intervention: 10ml aloe vera mouth wash (99.6% (w/v))
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.2% 10ml chlorhexidine mouth wash
Number of subjects: 30
Study: 34580499

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care for 3 hours after birth
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard postpartum procedure
Number of subjects: 112
Study: 32738887

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34637858

Group type: EXPERIMENTAL
Intervention: Midazolam (0.0125 mg.kg-1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo solution)
Number of subjects: 50
Study: 33562394

Group type: EXPERIMENTAL
Intervention: Vitamin D (20,000 IU of VD3/week for 24 weeks)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 35623017

Group type: EXPERIMENTAL
Intervention: Gratitude journaling
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Gratitude reflection
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: App prompted reflection
Number of subjects: 132

Group type: COMPARATOR
Intervention: Activity-matched control group
Number of subjects: 132
Study: 34549720

Group type: EXPERIMENTAL
Intervention: HFNC oxygen therapy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Nasal cannula oxygen therapy
Number of subjects: 178
Study: 33871015

Group type: EXPERIMENTAL
Intervention: Daily motivational text messages
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Motivational messages
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Feedback messages
Number of subjects: 93
Study: 32439224

Group type: EXPERIMENTAL
Intervention: propylene glycol (PG) + Lentulo
Number of subjects: 60

Group type: COMPARATOR
Intervention: distilled water (DW) + Lentulo
Number of subjects: 60
Study: 34470064

Group type: EXPERIMENTAL
Intervention: Cycled Lighting (CL)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Continuous Near Darkness (CND)
Number of subjects: 147
Study: 32017373

Group type: EXPERIMENTAL
Intervention: Horizontal orientation of the intraocular lens optic-haptic junctions at 180°
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard treatment (no manipulation of IOL orientation)
Number of subjects: 201
Study: 34558847

Group type: COMPARATOR
Intervention: Acetaminophen (APAP) 650 mg twice per day (1.3 g/day) for 4 days, followed by 650 mg on the morning of day 5.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (subjects without cirrhosis)
Number of subjects: 24
Study: 33086144

Group type: EXPERIMENTAL
Intervention: Behavioral activation with mindfulness (BAM)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 231
Study: 36135595

Group type: COMPARATOR
Intervention: PR (Periapical Radiography)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CBCT (Cone Beam Computed Tomography)
Number of subjects: 52
Study: 32299512

Group type: EXPERIMENTAL
Intervention: Brief psychiatric treatment (10 sessions over 4 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 34076401

Group type: EXPERIMENTAL
Intervention: ACU‐D1 (27 subjects)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparator vehicle (13 subjects)
Number of subjects: 40
Study: 34114154

Group type: EXPERIMENTAL
Intervention: Low-Residue Diet (LRD)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Clear Liquid Diet (CLD)
Number of subjects: 195
Study: 34907265

Group type: EXPERIMENTAL
Intervention: Ranibizumab (2 mg/0.05 ml) administered via 3 intravitreal injections at approximately 30-day intervals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study: 33252936

Group type: EXPERIMENTAL
Intervention: Savoring intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dampening intervention
Number of subjects: 100
Study: 33169444

Group type: EXPERIMENTAL
Intervention: 85% NMES
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 55% NMES
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25% NMES
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pseudo-stimulation
Number of subjects: 32
Study: 36315274

Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (135 mmol/L)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard dialysate sodium (138 mmol/L)
Number of subjects: 15
Study: 34398950

Group type: EXPERIMENTAL
Intervention: Neurolytic splanchnic nerve block with absolute alcohol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 96
Study: 35099566

Group type: EXPERIMENTAL
Intervention: Metal‐backed total knee arthroplasty (MBT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All‐polyethylene total knee arthroplasty (APT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Continuously migrating TKAs (9 implants)
Number of subjects: 115
Study: 32683594

Group type: EXPERIMENTAL
Intervention: BioFire® FilmArray® meningitis/encephalitis (FA‐ME) panel
Number of subjects: 142

Group type: COMPARATOR
Intervention: Separate molecular CSF microbiological tests (control group)
Number of subjects: 142
Study: 36241349

Group type: EXPERIMENTAL
Intervention: Natural cycle (NC)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Hormone replacement treatment (HT)
Number of subjects: 888
Study: 34157994

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (self-monitoring of daily steps plus counseling)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Single component intervention (self-monitoring of steps only)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 188
Study: 32340904

Group type: EXPERIMENTAL
Intervention: Leucine-rich supplement in combination with nutrition and physical exercise program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study: 34968819

Group type: EXPERIMENTAL
Intervention: Early oxytocin infusion following amniotomy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed oxytocin infusion following amniotomy
Number of subjects: 240
Study: 33346081

Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSMs) resected
Number of subjects: 109

Group type: COMPARATOR
Intervention: No cavity shave margins (no-shave)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Size of DCIS
Number of subjects: 109
Study: 34452964

Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 90
Study: 32646638

Group type: EXPERIMENTAL
Intervention: ACEI/ARB prescribed at discharge
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Beta blocker prescribed at discharge
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: MRA prescribed at discharge
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Outpatient clinic and HF disease management program review within 30 days
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Triple therapy prescribed
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Excellent guideline adherence score
Number of subjects: 696
Study: 35360482

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Longdan Xiegan decoction
Number of subjects: 50
Study: 32375905

Group type: EXPERIMENTAL
Intervention: 250 mg d-cycloserine (DCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35560310

Group type: EXPERIMENTAL
Intervention: Cocoa-based flavanols (FLV; 900 mg/d)
Number of subjects: 11
Study: 33900204

Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management including medication and CVD risk data from EHR, personalized risk score estimation, goal setting, self-monitoring, social forum, heart health messages.
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management (high users).
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Internet-based intervention for CVD management (high log-in frequency).
Number of subjects: 486
Study: 32417239

Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhagic transformation (HT)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Asymptomatic hemorrhagic transformation (HT)
Number of subjects: 448
Study: 35927020

Group type: EXPERIMENTAL
Intervention: Disadvantage indices for vaccine allocation
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Numerical anchor indicating expert recommendations
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Randomised condition without numerical anchor
Number of subjects: 2003
Study: 32643966

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Other nonsteroidal anti-inflammatory drugs
Number of subjects: 24081
Study: 34888861

Group type: EXPERIMENTAL
Intervention: Technology-Enhanced HNC (TE-HNC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 101
Study: 32679040

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 188
Study: 34773725

Group type: EXPERIMENTAL
Intervention: 755-nm picosecond laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1064-nm picosecond laser
Number of subjects: 20
Study: 33058366

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing based on risk prevention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 156
Study: 34156915

Group type: EXPERIMENTAL
Intervention: Hot shower application
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no hot shower)
Number of subjects: 104
Study: 34023008

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683
Study: 36380117

Group type: EXPERIMENTAL
Intervention: Soccer League (SL) intervention with 778 men attending soccer three times weekly for 6 months (72 sessions; 94% uptake, 45.5% weekly attendance rate) combined with an HIV/substance use cognitive-behavioral intervention.
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Control Condition (CC) with 415 men receiving educational materials and referrals at 3 month intervals.
Number of subjects: 1193
Study: 32618627

Group type: EXPERIMENTAL
Intervention: VR group (audiovisual distraction with a VR headset during induction)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No VR group (no audiovisual distraction)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 71
Study: 32409944

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard therapy without bevacizumab (Non-BEV)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment in first order recurrence
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard therapy without bevacizumab (Non-BEV) in first order recurrence
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) treatment in second or higher order recurrence
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard therapy without bevacizumab (Non-BEV) in second or higher order recurrence
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) overall survival multivariate analysis
Number of subjects: 61
Study: 32141785

Group type: EXPERIMENTAL
Intervention: 585 nm Pulsed Dye Laser (PDL)
Number of subjects: 30
Study: 34001166

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 21
Study: 35130291

Group type: EXPERIMENTAL
Intervention: BCD‐057
Number of subjects: 346

Group type: COMPARATOR
Intervention: iADA
Number of subjects: 346

Group type: COMPARATOR
Intervention: iADA/BCD‐057
Number of subjects: 346

Group type: COMPARATOR
Intervention: BCD‐057 and iADA
Number of subjects: 346

Group type: COMPARATOR
Intervention: iADA to BCD‐057 switch
Number of subjects: 346
Study: 34623254

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 300

Group type: COMPARATOR
Intervention: Microplegia
Number of subjects: 300
Study: 35768103

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training (RRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 33932804

Group type: EXPERIMENTAL
Intervention: Sardine group (SG) - 200 g of sardine per week
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Sardine group (SG)
Number of subjects: 152
Study: 32622225

Group type: EXPERIMENTAL
Intervention: Triage training for registered nurses and medical officer assistants
Number of subjects: 143
Study: 32601978

Group type: EXPERIMENTAL
Intervention: Treatment group (participants recalled other recently consumed foods to increase salience of dietary variety)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (participants recalled variety in an unrelated domain, music)
Number of subjects: 139
Study: 32315444

Group type: EXPERIMENTAL
Intervention: Delmopinol hydrochloride (DEL)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (CHX)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 89
Study: 35843287

Group type: COMPARATOR
Intervention: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE (Arm A)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Clear fluids + 2 L of polyethylene glycol (PEG) 12 hours before CE (Arm B)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Clear fluids + 1 L PEG + sodium ascorbate 3 hours before CE (Arm C)
Number of subjects: 229
Study: 32140989

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (≤ 10 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Long-course antibiotic therapy (28 days)
Number of subjects: 31
Study: 35016059

Group type: EXPERIMENTAL
Intervention: Ecologically realistic training based on pretend play (20 play sessions over 10 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 70
Study: 33040829

Group type: EXPERIMENTAL
Intervention: Guizhi Fuling Pills (L, M, H groups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 0
Study: 35749387

Group type: EXPERIMENTAL
Intervention: Health warning messages
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Environmental warning messages
Number of subjects: 1199
Study: 34900568

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33631978

Group type: EXPERIMENTAL
Intervention: Notebook covers illustrated with figures and informative texts about tooth avulsion and replantation
Number of subjects: 242
Study: 32737664

Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine (CHX) and 0.05% cetylpyridinium chloride (CPC) mouth rinse
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 54
Study: 33186451

Group type: EXPERIMENTAL
Intervention: 3 min of light-intensity walking every 30 minutes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 minutes of moderate-intensity walking every 30 minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prolonged sitting
Number of subjects: 18
Study: 34246118

Group type: EXPERIMENTAL
Intervention: Lacosamide (100–400 mg/day)
Number of subjects: 473
Study: 36304175

Group type: EXPERIMENTAL
Intervention: Preoperative oral saline administration (5 mL·kg−1 of normal saline 2 hours before anesthesia)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (forbidden from drinking 8 hours prior to the operation)
Number of subjects: 76
Study: 34803922

Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 9323
Study: 616774896

Group type: EXPERIMENTAL
Intervention: Vestibular electrical stimulation (VES) combined with medical treatment; 30 min long, twice a day, three times a week, for 12 sessions at 80 Hz TENS.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Medical treatment only (control group).
Number of subjects: 19
Study: 33039288

Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block (SAPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intercostal Nerve Block (ICNB)
Number of subjects: 40
Study: 35901339

Group type: EXPERIMENTAL
Intervention: Curcumin (800 mg twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 33393610

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 50
Study: 616062932

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic (EPA) and docosahexaenoic (DHA) polyunsaturated fatty acids supplementation (2.4g/d, 1.6 g EPA and 0.8 g DHA, ratio 2:1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 37244573

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue plus cord-anchored suture (SG group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suture alone (S group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (SG and S)
Number of subjects: 0
Study: 33865303

Group type: EXPERIMENTAL
Intervention: LDC cream (3% Defensil®, 5% dexpanthenol and ceramide)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5% urea cream
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LDC cream
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 34312153

Group type: EXPERIMENTAL
Intervention: Kilkari maternal messaging programme
Number of subjects: 4423

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 4423
Study: 32632894

Group type: EXPERIMENTAL
Intervention: Temozolomide plus short-course radiotherapy
Number of subjects: 562

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 562
Study: 35759691

Group type: EXPERIMENTAL
Intervention: Nitric oxide at 20 ppm delivered into the cardiopulmonary bypass oxygenator (n=679)
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Standard care cardiopulmonary bypass without nitric oxide (n=685)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Nitric oxide group
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 1371
Study: 34519661

Group type: EXPERIMENTAL
Intervention: Germ Defence intervention (open access website)
Number of subjects: 9779

Group type: COMPARATOR
Intervention: RCT intervention (automated digital intervention)
Number of subjects: 9779

Group type: EXPERIMENTAL
Intervention: Germ Defence intervention
Number of subjects: 9779

Group type: COMPARATOR
Intervention: RCT intervention
Number of subjects: 9779
Study: 32899117

Group type: EXPERIMENTAL
Intervention: hsa‐mir‐3614‐5p
Number of subjects: 14
Study: 35535242

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided QLB with 20 ml of 0.375% ropivacaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 84
Study: 33016996

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Tranexamic acid within 1 hour of injury
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo after 1 hour of injury
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Tranexamic acid in severe shock (systolic blood pressure ≤70 mm Hg)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo in severe shock (systolic blood pressure ≤70 mm Hg)
Number of subjects: 903
Study: 34344482

Group type: EXPERIMENTAL
Intervention: Impact loading exercises added to standard pulmonary rehabilitation programme (PRP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation programme (PRP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Impact loading exercises
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard maintenance exercises
Number of subjects: 58
Study: 34920451

Group type: EXPERIMENTAL
Intervention: Day 100 score (predictive score for moderate-severe cGVHD)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Day 100 score (predictive score for transplant-related mortality)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Day 100 score (predictive score for survival)
Number of subjects: 1292